Simplex Trading’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $95.2K | Buy |
+3,700
| New | +$76K | ﹤0.01% | 5605 |
|
|
2026
Q1 | – | Sell |
-51,700
| Closed | -$854K | – | 9296 |
|
|
2025
Q4 | $854K | Buy |
51,700
+48,300
| +1,421% | +$815K | ﹤0.01% | 2787 |
|
|
2025
Q3 | $49K | Sell |
3,400
-3,100
| -48% | -$44.5K | ﹤0.01% | 6475 |
|
|
2025
Q2 | $90K | Buy |
6,500
+5,000
| +333% | +$70.4K | ﹤0.01% | 5341 |
|
|
2025
Q1 | $20K | Sell |
1,500
-700
| -32% | -$13.4K | ﹤0.01% | 6573 |
|
|
2024
Q4 | $44K | Sell |
2,200
-5,100
| -70% | -$131K | ﹤0.01% | 6001 |
|
|
2024
Q3 | $212K | Buy |
7,300
+6,900
| +1,725% | +$171K | ﹤0.01% | 4462 |
|
|
2024
Q2 | $9K | Sell |
400
-28,000
| -99% | -$538K | ﹤0.01% | 7492 |
|
|
2024
Q1 | $582K | Buy |
28,400
+27,900
| +5,580% | +$524K | ﹤0.01% | 3698 |
|
|
2023
Q4 | $10K | Sell |
500
-800
| -62% | -$15.8K | ﹤0.01% | 7410 |
|
|
2023
Q3 | $26K | Sell |
1,300
-500
| -28% | -$12.7K | ﹤0.01% | 6384 |
|
|
2023
Q2 | $53K | Sell |
1,800
-4,100
| -69% | -$115K | ﹤0.01% | 5790 |
|
|
2023
Q1 | $135K | Sell |
5,900
-5,800
| -50% | -$160K | ﹤0.01% | 4803 |
|
|
2022
Q4 | $325K | Sell |
11,700
-700
| -6% | -$20.8K | ﹤0.01% | 3640 |
|
|
2022
Q3 | $380K | Buy |
12,400
+5,700
| +85% | +$185K | ﹤0.01% | 3794 |
|
|
2022
Q2 | $197K | Buy |
6,700
+5,700
| +570% | +$149K | ﹤0.01% | 4617 |
|
|
2022
Q1 | $32K | Buy |
1,000
+700
| +233% | +$24.1K | ﹤0.01% | 7693 |
|
|
2021
Q4 | $13K | Sell |
300
-100
| -25% | -$4.74K | ﹤0.01% | 8797 |
|
|
2021
Q3 | $31K | Hold |
400
| – | – | ﹤0.01% | 8058 |
|
|
2021
Q2 | $31K | Buy |
400
+356
| +809% | +$22K | ﹤0.01% | 8195 |
|
|
2021
Q1 | $251K | Buy |
+44
| New | +$2.94K | ﹤0.01% | 4393 |
|
|
2020
Q2 | – | Sell |
-43
| Closed | -$75K | – | 7735 |
|
|
2020
Q1 | $75K | Sell |
43
-277
| -87% | -$5.78K | ﹤0.01% | 4683 |
|
|
2019
Q4 | $557K | Buy |
320
+305
| +2,033% | +$5.08K | ﹤0.01% | 2634 |
|
|
2019
Q3 | $22K | Buy |
15
+11
| +275% | +$210 | ﹤0.01% | 5742 |
|
|
2019
Q2 | $8K | Buy |
4
+2
| +100% | +$45 | ﹤0.01% | 6217 |
|
|
2019
Q1 | $4K | Buy |
+2
| New | +$42 | ﹤0.01% | 6547 |
|
|
2018
Q3 | – | Sell |
-5
| Closed | -$7K | – | 7521 |
|
|
2018
Q2 | $7K | Buy |
+5
| New | +$94 | ﹤0.01% | 6521 |
|
Other funds holding DNLI
Simplex Trading's DNLI Position: Q2 2026 in Review
Simplex Trading increased its Denali Therapeutics (DNLI) stake by 94% in Q2 2026, buying an estimated $239K and bringing the position to 23,952 shares worth $616K. The position accounts for ﹤0.01% of the portfolio, ranked #3339.
Simplex Trading first reported a position in DNLI in Q3 2018 and has held it in 19 quarters since. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.
- Simplex Trading held 23,952 shares of Denali Therapeutics worth $616K as of Q2 2026.
- Simplex Trading bought 11,637 Denali Therapeutics shares in Q2 2026, an estimated $239K.
- Denali Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q2 2026, its #3339 holding.
- Simplex Trading first reported a position in Denali Therapeutics in Q3 2018 and has held it in 19 quarters since.
- 294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.
Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.